Intra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 Shares

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Chairman Sharon Mates sold 6,604 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $17.48, for a total value of $115,437.92. Following the completion of the transaction, the chairman now owns 1,088,707 shares of the company’s stock, valued at approximately $19,030,598.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Sharon Mates also recently made the following trade(s):

  • On Friday, January 5th, Sharon Mates sold 11,257 shares of Intra-Cellular Therapies stock. The shares were sold at an average price of $17.08, for a total value of $192,269.56.
  • On Monday, October 30th, Sharon Mates sold 18,750 shares of Intra-Cellular Therapies stock. The shares were sold at an average price of $15.75, for a total value of $295,312.50.

Intra-Cellular Therapies Inc. (ITCI) traded up $0.25 on Wednesday, hitting $18.37. The company had a trading volume of 373,900 shares, compared to its average volume of 497,171. The firm has a market capitalization of $1,000.00, a price-to-earnings ratio of -8.39 and a beta of 0.72. Intra-Cellular Therapies Inc. has a fifty-two week low of $7.85 and a fifty-two week high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.06 million. During the same period last year, the company earned ($0.70) EPS. The firm’s quarterly revenue was up 675.0% on a year-over-year basis. research analysts predict that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current year.

A number of large investors have recently modified their holdings of ITCI. Russell Investments Group Ltd. acquired a new stake in Intra-Cellular Therapies in the 3rd quarter worth about $101,000. SG Americas Securities LLC acquired a new stake in Intra-Cellular Therapies in the 2nd quarter worth about $103,000. Quantbot Technologies LP boosted its stake in Intra-Cellular Therapies by 233.1% in the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 6,028 shares during the last quarter. Fred Alger Management Inc. acquired a new stake in Intra-Cellular Therapies in the 2nd quarter worth about $161,000. Finally, Voya Investment Management LLC boosted its stake in Intra-Cellular Therapies by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 2,338 shares during the last quarter. 74.47% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently commented on the company. Zacks Investment Research lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Canaccord Genuity assumed coverage on Intra-Cellular Therapies in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Intra-Cellular Therapies presently has an average rating of “Buy” and an average target price of $25.56.

COPYRIGHT VIOLATION WARNING: “Intra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 Shares” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.com-unik.info/2018/01/10/intra-cellular-therapies-inc-itci-chairman-sharon-mates-sells-6604-shares.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit